Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 7, Issue 4, Pages 355-359Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2007.04.005
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI566223, R01 AI098519, R01 AI077395] Funding Source: Medline
Ask authors/readers for more resources
Glutathione (GSH) deficiency is associated with numerous pathological conditions. Administration of N-acetylcysteine (NAC), a cysteine prodrug, replenishes intracellular GSH levels. NAC, best known for its ability to counter acetaminophen toxicity, is a safe, well-tolerated antidote for cysteine/GSH deficiency. NAC has been used successfully to treat GSH deficiency in a wide range of infections, genetic defects and metabolic disorders, including HIV infection and COPD. Over two-thirds of 46 placebo-controlled clinical trials with orally administered NAC have indicated beneficial effects of NAC measured either as trial endpoints or as general measures of improvement in quality of life and well-being of the patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available